WHO ICTRP trial

A study to explore heart function during first dose administration of fingolimod…

EUCTR2012-000653-32-DE · EU Clinical Trials Register · Not Recruiting

Key facts

Trial ID EUCTR2012-000653-32-DE
Public title A study to explore heart function during first dose administration of fingolimod in patients with relapsing-remitting multiple sclerosis
Scientific title A 1-week, open-label, multi-center study to explore conduction abnormalities during first dose administration of fingolimod in patients with relapsing-remitting multiple sclerosis (START) - START
Primary sponsor Novartis Pharma GmbH
Registry EU Clinical Trials Register
Recruitment status Not Recruiting
Study type Interventional clinical trial of medicinal product
Phase Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): yes
Countries Germany
Conditions Conduction abnormalities in patients with relapsing-remitting multiple sclerosis MedDRA version: 18.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system…
Interventions Trade Name: Gilenya Product Name: Fingolimod Product Code: FTY720 Pharmaceutical Form: Capsule, hard CAS Number: 162359-56-0 Current Sponsor code: FTY720 Other descriptive name: Fingolimod Hydrochloride Concentration unit: mg milligram(s)…
Registration date Dec 4, 2012
Secondary IDs CFTY720DDE17
Registry page clinicaltrialsregister.eu

At a glance

  • No Results available

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About WHO ICTRP trial registrations

The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.

Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date:

Browse all WHO ICTRP trial registrations